| Line 160: | Line 160: | ||
*Referring to: Varella MH, Andrade OA, Shaffer SM, Castro G, Rodriguez P, Barengo NC, Acuna JM. E-cigarette use and respiratory symptoms in residents of the United States: A BRFSS report. PLoS One. 2022 Dec 1;17(12):e0269760. doi: 10.1371/journal.pone.0269760. PMID: 36454742; PMCID: PMC9714717. | *Referring to: Varella MH, Andrade OA, Shaffer SM, Castro G, Rodriguez P, Barengo NC, Acuna JM. E-cigarette use and respiratory symptoms in residents of the United States: A BRFSS report. PLoS One. 2022 Dec 1;17(12):e0269760. doi: 10.1371/journal.pone.0269760. PMID: 36454742; PMCID: PMC9714717. | ||
===2019-2020: [https://pubpeer.com/publications/7571819CEB7A2BC425BE3D7061410D Association of E-Cigarette Use With Respiratory Disease Among Adults: A Longitudinal Analysis]=== | ===2019-2020: RE: [https://pubpeer.com/publications/7571819CEB7A2BC425BE3D7061410D Association of E-Cigarette Use With Respiratory Disease Among Adults: A Longitudinal Analysis]=== | ||
*Multiple Comments: | *Multiple Comments: | ||
**"One of the essential criteria of causal inference is that exposure to the cause precedes disease onset. Three of the diseases Glantz studies — COPD, chronic bronchitis and emphysema — take decades to become clinically apparent and would have been present, even though undiagnosed, in many of his cases long before his study began in 2014, and indeed even before e-cigarettes first became available in the US in about 2007. His findings are also flawed by the fact that most vapers have smoked, and since smoking is a strong cause of chronic lung disease, vapers inevitably carry an increased risk of lung disease long after quitting smoking. Glantz claims to have allowed for this statistically but his approach is simplistic: he lacks the detail of lifetime duration and intensity of smoking required. On these grounds alone his conclusion is specious." (Britton) | **"One of the essential criteria of causal inference is that exposure to the cause precedes disease onset. Three of the diseases Glantz studies — COPD, chronic bronchitis and emphysema — take decades to become clinically apparent and would have been present, even though undiagnosed, in many of his cases long before his study began in 2014, and indeed even before e-cigarettes first became available in the US in about 2007. His findings are also flawed by the fact that most vapers have smoked, and since smoking is a strong cause of chronic lung disease, vapers inevitably carry an increased risk of lung disease long after quitting smoking. Glantz claims to have allowed for this statistically but his approach is simplistic: he lacks the detail of lifetime duration and intensity of smoking required. On these grounds alone his conclusion is specious." (Britton) | ||
edits